A Randomized, Open-Label, Two-Period, Two-Sequence, Crossover Bioequivalence Study of Amoxicillin-Clavulanate Film-Coated Tablets in Healthy Volunteers Under Fed Conditions

The primary objective of this study is to evaluate the **bioequivalence** of two formulations of amoxicillin-clavulanic acid film-coated tablets in healthy volunteers under fed conditions. This is clinically relevant as establishing bioequivalence ensures that the two formulations can be used interchangeably, maintaining therapeutic efficacy and safety in treating **infections**. No secondary objectives are provided in the available data.

The clinical trial involves a study population comprising both **male** and **female** participants, with an age range categorized under code "3," which typically includes adults. The trial includes a **vulnerable population**, indicating that special considerations are in place for participants who may require additional protections. The study focuses on individuals with **infections**. However, the sponsor has not provided specific information regarding the total number of participants or detailed lifestyle considerations such as diet, physical activity, or habits. Additionally, key inclusion or exclusion criteria have not been disclosed. The selection process for the trial population remains unspecified, and the main objective of the trial has not been detailed by the sponsor.

The clinical trial is designed as a **randomized**, open-label, two-period, two-sequence, crossover study to evaluate the bioequivalence of two formulations of amoxicillin-clavulanic acid film-coated tablets in healthy volunteers under fed conditions. The trial is categorized as a Phase 2 study and is expected to commence recruitment on July 4, 2025, with an estimated completion date of August 15, 2025. The primary medical condition under investigation is **infections**, with a focus on assessing the pharmacokinetic parameters of the drug formulations.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as the screening phase to determine eligibility based on predefined criteria. Following successful screening, participants will be randomized into one of two sequences for the crossover design. Each participant will receive a single dose of one formulation in the first period, followed by a washout phase, and then receive the alternate formulation in the second period. The study will include follow-up visits to monitor safety and collect pharmacokinetic data. The end-of-study visit will conclude the participant's involvement, ensuring all necessary data is collected and any adverse events are addressed.

The expected duration of participant involvement is approximately six weeks, accounting for the screening, dosing, washout, and follow-up periods. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The study aims to provide robust data on the bioequivalence of the two formulations, contributing to the understanding of their pharmacokinetic profiles in the context of treating infections.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the provided data, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be elaborated upon. The trial documentation should be consulted for comprehensive information regarding the treatments involved in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on July 4, 2025, with an estimated completion date of August 15, 2025. The efficacy assessment will be conducted through a series of predefined parameters, although specific endpoints are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for assessment, are not specified in the provided information. The trial will adhere to rigorous standards to evaluate the therapeutic impact of the intervention under investigation.